Circulating Tumor DNA Predicts Progression-Free Survival in Hodgkin Lymphoma
A validated sequencing assay identifies patients at high risk for relapse after two cycles of chemotherapy in the GHSG HD21 trial.
Gene Expression Score Predicts Survival in Myelofibrosis
A 24-gene signature derived from stem cells identifies high-risk patients missed by current clinical and mutation-based scoring systems.
JMJD1C Deficiency Drives Pathogenic Antibody Production in Heparin-Induced Thrombocytopenia
Loss of the histone demethylase JMJD1C triggers B-cell hyperactivation and the production of platelet-activating antibodies.
Beti-cel Gene Therapy Sustains Transfusion Independence for Up to Ten Years
Long-term data show 90.2% of phase 3 patients achieved transfusion independence with stable hemoglobin and improved iron homeostasis.
POT1 Mutations Drive Lymphoid Malignancy Through Ultralong Telomeres
Pathogenic POT1 variants increase lymphoma risk eightfold by extending cellular longevity and promoting age-dependent clonal expansion.
Ruxolitinib Resolves Severe Diarrhea Following BCMA-Targeted CAR T-Cell Therapy
A case series suggests JAK inhibition may mitigate the high mortality associated with immune-mediated enterocolitis in multiple myeloma.
NXT007 Reaches Nonhemophilic Factor VIII Levels in Severe Hemophilia A
A phase 1/2 trial shows monthly subcutaneous NXT007 achieves factor activity above 40 IU/dL and eliminates bleeds at higher doses.
Interleukin-4 Inhibits Platelet Glycoprotein VI to Reduce Thrombosis in Mice
The anti-inflammatory cytokine IL-4 binds directly to the GPVI receptor, suppressing collagen-induced activation and clot formation.
Integrated Genetics and MRD Guide Transplant in Ph-Negative ALL
A prospective study shows that combining genetic risk with early molecular response identifies adults who can safely avoid transplantation.
RNA Interference Normalizes PAI-1 Levels and Prolongs Lifespan in Murine Models
A single dose of siRNA-lipid nanoparticles achieved 90% knockdown of plasma PAI-1, reducing thrombus weight and increasing survival in mice.
Triplet Immunotherapy Shows Durable Response in Relapsed Hodgkin Lymphoma
Adding ipilimumab to nivolumab and brentuximab vedotin may improve long-term disease control for patients deferring stem cell transplant.
Immune Score Predicts Infection Risk in Multiple Myeloma
A three-factor immune profile identifies patients with a 60% infection incidence, offering a path to personalized prophylaxis.